Arcturus Therapeutics Holdings Stock Performance
| ARCT Stock | USD 7.17 0.23 3.11% |
Arcturus Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arcturus Therapeutics will likely underperform. Arcturus Therapeutics right now shows a risk of 3.7%. Please confirm Arcturus Therapeutics information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Arcturus Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Arcturus Therapeutics Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Arcturus Therapeutics may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return (3.11) | Five Day Return (0.97) | Year To Date Return 14.72 | Ten Year Return (81.74) | All Time Return (86.43) |
Last Split Factor 1:7 | Dividend Date 2017-11-16 | Last Split Date 2017-11-16 |
1 | Acquisition by Sassine Andy of 1238 shares of Arcturus Therapeutics at 16.558 subject to Rule 16b-3 | 11/14/2025 |
2 | Acquisition by Sassine Andy of 1068 shares of Arcturus Therapeutics at 18.4195 subject to Rule 16b-3 | 12/03/2025 |
3 | Acquisition by Lance Kurata of 54000 shares of Arcturus Therapeutics at 6.52 subject to Rule 16b-3 | 12/17/2025 |
4 | Acquisition by Chivukula Pad of 54000 shares of Arcturus Therapeutics at 6.52 subject to Rule 16b-3 | 12/19/2025 |
5 | Arcturus Therapeutics Holdings files for mixed shelf of up to 500 million - SEC filing - marketscreener.com | 12/30/2025 |
6 | Arcturus Therapeutics Holdings Inc. Receives 36.00 Average PT from Analysts | 01/07/2026 |
7 | Is Arcturus Therapeutics Using Its 500 Million Shelf to Redefine Capital Strategy - Yahoo Finance | 01/12/2026 |
8 | Does Arcturus Therapeutics JPM Conference Spotlight Clarify Its Long-Term Platform Credibility | 01/14/2026 |
9 | Acquisition by Markels John of 15000 shares of Arcturus Therapeutics at 12.54 subject to Rule 16b-3 | 01/16/2026 |
10 | RothMKM initiates coverage on Arcturus Therapeutics stock with Buy rating - Investing.com | 01/23/2026 |
11 | Acquisition by Payne Joseph E of 175000 shares of Arcturus Therapeutics at 6.52 subject to Rule 16b-3 | 01/29/2026 |
12 | Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. Pipeline Assets | 02/02/2026 |
13 | Arcturus Therapeutics Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha | 02/12/2026 |
| Begin Period Cash Flow | 348.9 M | |
| Total Cashflows From Investing Activities | -648 K |
Arcturus Therapeutics Relative Risk vs. Return Landscape
If you would invest 676.00 in Arcturus Therapeutics Holdings on November 15, 2025 and sell it today you would earn a total of 41.00 from holding Arcturus Therapeutics Holdings or generate 6.07% return on investment over 90 days. Arcturus Therapeutics Holdings is currently generating 0.1648% in daily expected returns and assumes 3.6957% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Arcturus, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcturus Therapeutics Target Price Odds to finish over Current Price
The tendency of Arcturus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.17 | 90 days | 7.17 | about 43.79 |
Based on a normal probability distribution, the odds of Arcturus Therapeutics to move above the current price in 90 days from now is about 43.79 (This Arcturus Therapeutics Holdings probability density function shows the probability of Arcturus Stock to fall within a particular range of prices over 90 days) .
Arcturus Therapeutics Price Density |
| Price |
Predictive Modules for Arcturus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arcturus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcturus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcturus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Arcturus Therapeutics is not an exception. The market had few large corrections towards the Arcturus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arcturus Therapeutics Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arcturus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.39 | |
β | Beta against Dow Jones | 2.26 | |
σ | Overall volatility | 0.64 | |
Ir | Information ratio | -0.08 |
Arcturus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arcturus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arcturus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Arcturus Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 138.39 M. Net Loss for the year was (80.94 M) with loss before overhead, payroll, taxes, and interest of (94.39 M). | |
| Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (59.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Arcturus Therapeutics Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha |
Arcturus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arcturus Stock often depends not only on the future outlook of the current and potential Arcturus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arcturus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 237 M |
Arcturus Therapeutics Fundamentals Growth
Arcturus Stock prices reflect investors' perceptions of the future prospects and financial health of Arcturus Therapeutics, and Arcturus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcturus Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 55.61 M | ||||
| Shares Outstanding | 28.41 M | ||||
| Price To Earning | 119.50 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 2.09 X | ||||
| Revenue | 138.39 M | ||||
| Gross Profit | (94.39 M) | ||||
| EBITDA | (77.4 M) | ||||
| Net Income | (80.94 M) | ||||
| Cash And Equivalents | 283.49 M | ||||
| Cash Per Share | 10.67 X | ||||
| Total Debt | 28.55 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 3.14 X | ||||
| Book Value Per Share | 8.24 X | ||||
| Cash Flow From Operations | (59.75 M) | ||||
| Earnings Per Share | (2.39) X | ||||
| Market Capitalization | 203.73 M | ||||
| Total Asset | 344.07 M | ||||
| Retained Earnings | (448.81 M) | ||||
| Working Capital | 240.49 M | ||||
| Current Asset | 54.55 M | ||||
| Current Liabilities | 3.52 M | ||||
About Arcturus Therapeutics Performance
Assessing Arcturus Therapeutics' fundamental ratios provides investors with valuable insights into Arcturus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcturus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.2 K | 1.2 K | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.30) | (0.32) |
Things to note about Arcturus Therapeutics performance evaluation
Checking the ongoing alerts about Arcturus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcturus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcturus Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 138.39 M. Net Loss for the year was (80.94 M) with loss before overhead, payroll, taxes, and interest of (94.39 M). | |
| Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (59.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Arcturus Therapeutics Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha |
- Analyzing Arcturus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcturus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arcturus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcturus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcturus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcturus Therapeutics' stock. These opinions can provide insight into Arcturus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.